Salix Pharmaceuticals Ltd. (SLXP), Monday reported a wider net loss for the third quarter, as higher expenses offset the positive impact of higher revenue. The company also reaffirmed its outlook for fiscal 2009.
Salix Pharmaposted a net loss of $7.3 million or $0.15 per share for the third quarter of 2009, compared to a loss of $5.4 million or $0.11 per share in the prior year quarter. On average, 9 analysts polled by Thomson Reuters expected the company to report a loss of $0.29 per share for the third quarter. Analysts' estimates typically exclude special items.
Third quarter total product revenue soared 53% to $65.7 million from $42.9 million in the third quarter of 2008. Nine analysts had a consensus revenue estimate of $60.42 million for the third quarter.
As a percentage of sales, gross margin on total product revenue dropped to 79.9% from 81.9% in the previous year quarter.
Total costs and expenses increased 49% to $71.5 million from $47.9 million in the year-ago quarter.
For the nine-month period of 2009, the company reported a net loss of $36.6 million or $0.76 per share, compared to a loss of $36.5 million or $0.76 per share in the previous year period.
Net product revenue increased to $162.7 million from $118.2 million in the prior year period.
For the fourth quarter of 2009, the company anticipates a loss of about $0.14 per share, and total company product revenue of about $68 million. The Street currently estimates a loss of $0.03 per share on revenue of $72.28 million for the fourth quarter.
For fiscal year 2009, the company continues to expect a loss of $0.90 per share and total company product revenue to be about $230 million, representing 29% growth over last year. Analysts currently project a loss of $0.92 per share on revenue of $230.18 million for the year 2009.
SLXP closed Monday's regular trading session at $21.14, up 20 cents. In after-hours, the share further gained 16 cents.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.